Targeting Apoptosis Pathways With BCL2 and MDM2 Inhibitors in Adult B-cell Acute Lymphoblastic Leukemia

Targeting Apoptosis Pathways With BCL2 and MDM2 Inhibitors in Adult B-cell Acute Lymphoblastic Leukemia

In adult patients, the treatment outcome of acute lymphoblastic leukemia (ALL) remains suboptimal. Here, we used an ex vivo drug testing platform and comprehensive molecular profiling to discover new drug candidates for B-ALL. We analyzed sensitivity of 18 primary B-ALL adult patient samples to 64 d...

Full description

Bibliographic Details
Main Authors:	Helena Hohtari, Matti Kankainen, Shady Adnan-Awad, Bhagwan Yadav, Swapnil Potdar, Aleksandr Ianevski, Olli Dufva, Caroline Heckman, Veronika Sexl, Soili Kytölä, Satu Mustjoki, Kimmo Porkka
Format:	Article
Language:	English
Published:	Wiley 2022-03-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/HS9.0000000000000701

Similar Items

P1228: GENOME-WIDE CRISPR-CAS9 SCREENING IDENTIFIES THERAPEUTIC TARGETS FOR MATURE T-CELL MALIGNANCIES
by: Sanna Timonen, et al.
Published: (2023-08-01)

Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation
by: Shady Adnan Awad, et al.
Published: (2022-04-01)

P409: BCL-2/BCL-XL INHIBITION INDUCES APOPTOSIS AND CIRCUMVENTS VENETOCLAX RESISTANCE IN TP53-MUTATED ACUTE MYELOID LEUKEMIA
by: Ida Vänttinen, et al.
Published: (2023-08-01)

Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia
by: Brian S. White, et al.
Published: (2021-07-01)

MDM2-BCL-XL PROTACs enable degradation of BCL-XL and stabilization of p53
by: Mengyang Chang, et al.
Published: (2022-08-01)

The impact of RNA sequence library construction protocols on transcriptomic profiling of leukemia
by: Ashwini Kumar, et al.
Published: (2017-08-01)

Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia.
by: Mohamed El Missiry, et al.
Published: (2017-01-01)

Comparison of Structural and Short Variants Detected by Linked-Read and Whole-Exome Sequencing in Multiple Myeloma
by: Ashwini Kumar, et al.
Published: (2021-03-01)

S151: HIGH-THROUGHPUT EVALUATION OF THE POTENTIAL OF CANCER DRUGS TO ENHANCE NATURAL KILLER CELL IMMUNOTHERAPY IN CHRONIC MYELOID LEUKEMIA.
by: P. Nygren, et al.
Published: (2022-06-01)

Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
by: Olli Dufva, et al.
Published: (2018-04-01)

The MDM2-binding region in the transactivation domain of p53 also acts as a Bcl-XL-binding motif
by: Xu, Huibin, et al.
Published: (2012)

RBP2 Promotes Adult Acute Lymphoblastic Leukemia by Upregulating BCL2.
by: Xiaoming Wang, et al.
Published: (2016-01-01)

Immunohistochemical localization of mdm-2, p27<sup>Kip1 </sup>and bcl-2 in Warthin's tumor of the parotid gland
by: Elshafei Marwa M, et al.
Published: (2009-05-01)

Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells
by: Zuzana Mrkvová, et al.
Published: (2019-06-01)

Therapeutic Targeting of MERTK and BCL-2 in T-Cell and Early T-Precursor Acute Lymphoblastic Leukemia
by: Ryan J. Summers, et al.
Published: (2022-12-01)

Impact of the MDM2 splice-variants MDM2-A, MDM2-B and MDM2-C on cytotoxic stress response in breast cancer cells
by: Johanna Huun, et al.
Published: (2017-04-01)

T and NK cell abundance defines two distinct subgroups of renal cell carcinoma
by: Moon Hee Lee, et al.
Published: (2022-12-01)

Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profile.
by: Anna Kreutzman, et al.
Published: (2011-01-01)

IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia
by: Jani Huuhtanen, et al.
Published: (2022-09-01)

The Functional Roles of the MDM2 Splice Variants P2-MDM2-10 and MDM2-∆5 in Breast Cancer Cells
by: Johanna Huun, et al.
Published: (2017-10-01)

The p53–Mdm2 interaction and the E3 ligase activity of Mdm2/Mdm4 are conserved from lampreys to humans
by: Venkatesh, Byrappa, et al.
Published: (2016)

The acute lymphoblastic leukemia prognostic scoring whether it is possible by BCL-2, BAX gene promoter genotyping
by: Mozhgan Moazami-Goudarzi, et al.
Published: (2016-04-01)

Hinokiflavone Inhibits MDM2 Activity by Targeting the MDM2-MDMX RING Domain
by: Viktoria K. Ilic, et al.
Published: (2022-04-01)

MDM2, MDM4 and EGFR Amplifications and Hyperprogression in Metastatic Acral and Mucosal Melanoma
by: Andrea Forschner, et al.
Published: (2020-02-01)

MDM2 inhibitors: Targeting p53-MDM2 interaction to anti-cancer
by: Zhang Xulin
Published: (2021-01-01)

MLL-rearranged acute lymphoblastic leukemias activate BCL-2 through H3K79 methylation and are sensitive to the BCL-2-specific antagonist ABT-199
by: Benito, J, et al.
Published: (2015)

Bioimpedance spinal needle provides high success and low complication rate in lumbar punctures of pediatric patients with acute lymphoblastic leukemia
by: Satu Långström, et al.
Published: (2022-04-01)

The MDM2 gene family
by: Mendoza Michael, et al.
Published: (2014-03-01)

Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models
by: Christian Lehmann, et al.
Published: (2016-06-01)

Molecular mechanism of CCDC106 regulating the p53-Mdm2/MdmX signaling axis
by: Ting Zhou, et al.
Published: (2023-12-01)

Modulators of the p53-MDM2 interaction : search for MDM2 interactors using structural guidance
by: Lin, Jianqing
Published: (2014)

The dual interactions of p53 with MDM2 and p300 : implications for the design of MDM2 inhibitors
by: Kannan, Srinivasaraghavan, et al.
Published: (2020)

p53 Phosphomimetics Preserve Transient Secondary Structure but Reduce Binding to Mdm2 and MdmX
by: Robin Levy, et al.
Published: (2019-03-01)

A Call for Explainer/Tutorial Articles and Changes to Manuscript Submission and Review at MDM and MDM P&P
by: Brian J. Zikmund-Fisher
Published: (2020-10-01)

PB1749: APOPTOTIC EFFECT OF FLUMATINIB COMBINED WITH BCL2 INHIBITOR ON PH+ B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
by: Y. Gu, et al.
Published: (2022-06-01)

Mdm2 widens its repertoire.
by: Coutts, A, et al.
Published: (2007)

THE OXFORD MDM-2 MAGNETIC SPECTROMETER
by: Pringle, D, et al.
Published: (1986)

Exome Sequencing Identifies Susceptibility Loci for Sarcoidosis Prognosis
by: Elisa Lahtela, et al.
Published: (2019-12-01)

Associations of <i>MDM2</i> and <i>MDM4</i> Polymorphisms with Early-Stage Breast Cancer
by: Agnė Bartnykaitė, et al.
Published: (2021-02-01)

Assessing the Efficacy of Mdm2/Mdm4-Inhibiting Stapled Peptides Using Cellular Thermal Shift Assays
by: Brown, Christopher J., et al.
Published: (2015)